Related Experiment Video
Updated: Jun 3, 2025
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Interleukin-6 Modulation in Ovarian Cancer Necessitates a Targeted Strategy: From the Approved to Emerging Therapies
Hina Amer1, Nirmala C Kampan2, Catherine Itsiopoulos1
1School of Health and Biomedical Sciences, RMIT University, Bundoora, VIC 3082, Australia.
Abstract:
Despite significant advances in treatments, ovarian cancer (OC) remains one of the most prevalent and lethal gynecological cancers in women. The frequent detection at the advanced stages has contributed to low survival rates, resistance to various treatments, and disease recurrence. Thus, a more effective approach is warranted to combat OC. The cytokine Interleukin-6 (IL6) has been implicated in various stages of OC development. High IL6 levels are also correlated with a lower survival rate in OC patients. In this current review, we summarized the pivotal roles of IL6 in OC, including the initiation, development, invasion, metastasis, and drug resistance mechanisms. This article systematically highlights how targeting IL6 improves OC outcomes by altering various cancer processes and reports the ongoing clinical trials that would further shape the IL6-based targeted therapies. This review also suggests how combining IL6-targeted therapies with other therapeutic strategies could further enhance their efficacy to combat OC.
Insights
Interleukin-6 (IL6) drives ovarian cancer progression and resistance. Targeting IL6 offers a promising therapeutic strategy to improve patient outcomes and overcome treatment challenges in ovarian cancer.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Ovarian cancer (OC) is a leading cause of gynecological cancer deaths, often diagnosed at advanced stages.
- Low survival rates and treatment resistance are significant challenges in managing OC.
- Interleukin-6 (IL6) is a cytokine implicated in OC development and progression.
Purpose of the Study:
- To review the multifaceted roles of IL6 in ovarian cancer.
- To highlight IL6-targeted therapies for improving OC outcomes.
- To discuss ongoing clinical trials and combination strategies for IL6-based treatments.
Main Methods:
- Systematic review of scientific literature.
- Analysis of IL6's involvement in OC initiation, development, invasion, metastasis, and drug resistance.
- Summary of current clinical trials and therapeutic strategies targeting IL6.
Main Results:
- IL6 plays a pivotal role in various stages of ovarian cancer.
- High IL6 levels correlate with poorer survival rates in OC patients.
- Targeting IL6 demonstrates potential to alter cancer processes and improve treatment efficacy.
Conclusions:
- IL6 is a critical mediator in ovarian cancer progression and therapeutic resistance.
- Targeting IL6 presents a viable strategy to enhance ovarian cancer treatment outcomes.
- Combination therapies involving IL6 inhibition may offer synergistic benefits for ovarian cancer patients.
More Related Videos
07:59Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1
Published on: December 5, 2020
10:35An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses
Published on: November 28, 2010
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...